The claim that retatrutide is a triple G peptide is robustly supported by peer-reviewed literature. The 2024 Melson et al. review in International Journal of Obesity explicitly confirms retatrutide's mechanism as a GLP-1/GIP/glucagon triple receptor agonist and documents its progression to Phase III obesity trials. This is not speculative or marketing language—it is the consensus characterization in published clinical reviews. The 'triple G' terminology accurately reflects the scientific designation of its receptor profile.
Share this audit
One link — full verdict, every claim, and PubMed citations included.
Shareable link includes the full verdict, claims, and PubMed citations.
Post captionshow
Retatrutide: the new triple G peptide is blowing up in fitness circles, but here’s what most aren’t telling you. It’s still investigational, not approved. Buying online? You’re skipping real safety systems—risk skyrockets.
Bottom line: Don’t gamble with your health on gray market injectables. Get medical supervision, protect your muscle, and build real habits.
#Retatrutide #tripleagonist #peptid…
Show full post caption
es #weightloss #leanmuscle
Show lessVideo transcript not captured. This audit used the caption only. For a fuller audit, run a new check and paste the spoken transcript.
Claim breakdown
1 claim“Retatrutide is a triple G peptide”
Multiple peer-reviewed sources directly confirm retatrutide is a triple GLP-1/GIP/glucagon receptor agonist. The 2024 Melson et al. review (PMID: 38302593) in Int J Obes explicitly states: 'the triple agonist retatrutide (GLP-1/GIP/glucagon RA)' and notes it has 'progressed to phase 3 trials as obesity treatments.' The Elmendorf et al. IUPHAR review (2026, Pharmacol Res) provides additional peer-reviewed confirmation of this mechanism class. PeptIQ's internal profile corroborates this as Eli Lilly's LY3437943 triple agonist currently in Phase III trials.
Supporting studies
- 1
What is the pipeline for future medications for obesity?
International journal of obesity (2005) · 2025·PMID 38302593
- 2
IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes
Pharmacological research · 2026·PMID 41478576
- 3
Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review
World journal of gastroenterology · 2025·PMID 41025003
- 4
Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies
Medicines (Basel, Switzerland) · 2025·PMID 40843857
- 5
Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge
American journal of physiology. Gastrointestinal and liver physiology · 2025·PMID 41056349
This audit is for educational purposes only. Not medical advice. Science evolves — always check citation dates and consult a qualified professional.
Report an error